SGN-15 - Seagen
Rituxan (rituximab) - Biogen, Zenyaku Holdings, Roche
Adcetris (brentuximab vedotin) - Seagen, Takeda
Polivy (polatuzumab vedotin-piiq) - Roche
Cyrevia (cyclophosphamide high dose) - Accentia
https://www.targetedonc.com/view/treatment-considerations-in-primary-refractory-vs-early-relapsed-dlbcl
 
Joseph M Tuscano; Mujahid Rizvi; Gigi Chen; Ming Zhou; Diana Superfin; Chainarong Limvarapuss
 
Jul 25, 2023
 
Prev Next